Cargando…

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index

Detalles Bibliográficos
Autores principales:	Wang, Yucai, Achenbach, Sara J., Rabe, Kari G., Shanafelt, Tait D., Call, Timothy G., Ding, Wei, Kenderian, Saad S., Muchtar, Eli, Leis, Jose F., Koehler, Amber B., Schwager, Susan M., Cerhan, James R., Slager, Susan L., Kay, Neil E., Parikh, Sameer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342603/ https://www.ncbi.nlm.nih.gov/pubmed/34354039 http://dx.doi.org/10.1038/s41408-021-00532-1

Ejemplares similares

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
por: King, Rebecca L., et al.
Publicado: (2022)

Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center
por: Wang, Yucai, et al.
Publicado: (2020)

Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans
por: Kleinstern, Geffen, et al.
Publicado: (2021)

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
por: Parikh, Sameer A., et al.
Publicado: (2020)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

The role of (18)F-FDG-PET in detecting Richter transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor
por: Wang, Yucai, et al.
Publicado: (2020)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
por: Hampel, Paul J., et al.
Publicado: (2021)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Immnuophenotypic and Gene Expression Analysis of Monoclonal B Cell Lymphocytosis Shows Biologic Characteristics Associated With Good Prognosis CLL
por: Lanasa, Mark C., et al.
Publicado: (2011)

Risk of Non-hematologic Cancer in Individuals with High Count Monoclonal B-Cell Lymphocytosis (MBL)
por: Solomon, Benjamin M., et al.
Publicado: (2015)

An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)
por: Ruan, Gordon, et al.
Publicado: (2022)

The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis
por: Parikh, Sameer A., et al.
Publicado: (2022)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
por: Wang, Yucai, et al.
Publicado: (2021)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis
por: Boddicker, Nicholas J., et al.
Publicado: (2022)

Progression and survival of MBL: a screening study of 10 139 individuals
por: Slager, Susan L., et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER
por: Audil, H., et al.
Publicado: (2022)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m5f5bmr45avi7g7tk32kkdroil